ストックスクリーナーアプリを入手
265.00
0.45%
1.20
プレマーケット:
263.00
-2.00
-0.75%
前日終値:
$263.80
開ける：
$266.93
24時間の取引高:
234.79K
Relative Volume:
0.79
時価総額：
$7.75B
収益：
$290.51M
当期純損益:
$89.16M
株価収益率:
88.63
EPS:
2.99
ネットキャッシュフロー:
$119.18M
1週間 パフォーマンス:
-2.75%
1か月 パフォーマンス:
-1.53%
6か月 パフォーマンス:
+76.96%
1年 パフォーマンス:
+51.24%
1日の値動き範囲:
$257.44
$266.99
1週間の範囲:
$253.70
$277.03
52週間の値動き範囲:
$122.80
$298.30
Krystal Biotech Inc Stock (KRYS) Company Profile
名前
Krystal Biotech Inc
セクター
電話
(412) 586-5830
住所
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
265.00 | 7.71B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-06 | アップグレード | Citigroup | Neutral → Buy |
| 2025-03-05 | 開始されました | Jefferies | Buy |
| 2024-08-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 開始されました | Citigroup | Buy |
| 2023-09-07 | 開始されました | Berenberg | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2023-02-28 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-25 | ダウングレード | Goldman | Buy → Neutral |
| 2022-01-18 | 開始されました | BofA Securities | Buy |
| 2021-07-20 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-18 | 開始されました | B. Riley FBR | Buy |
| 2020-06-04 | 開始されました | Evercore ISI | Outperform |
| 2019-09-24 | 開始されました | Goldman | Neutral |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-24 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-30 | 開始されました | Guggenheim | Buy |
| 2018-09-11 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Krystal Biotech Inc (KRYS) 最新ニュース
[144] Krystal Biotech, Inc. SEC Filing - Stock Titan
Segall Bryant & Hamill LLC Lowers Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech at TD Cowen Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Kathryn Romano Sells 750 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Daniel Janney Sells 11,803 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Daniel Janney sells Krystal Biotech (KRYS) shares worth $3.25 million - Investing.com
Krystal Biotech (KRYS) CAO sells shares and receives fresh stock awards - Stock Titan
Krystal Biotech (KRYS) R&D chief logs new awards, PSU vesting and tax trades - Stock Titan
Krystal Biotech (NASDAQ: KRYS) CEO reports new equity awards and tax share surrenders - Stock Titan
Alta Bioequities linked to Krystal Biotech (KRYS) director sells 11,803 shares - Stock Titan
Krystal Biotech, Inc. $KRYS Position Increased by William Blair Investment Management LLC - MarketBeat
TD Asset Management Boosts Stake in Krystal Biotech - National Today
TD Asset Management Inc Boosts Position in Krystal Biotech, Inc. $KRYS - MarketBeat
KRYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kathryn Romano sells 12,500 KRYS shares (NASDAQ: KRYS); 750 more vest - Stock Titan
Krystal Biotech, Inc. (KRYS) Stock Analysis: A Promising Genetic Medicine Leader with 13.63% Potential Upside - DirectorsTalk Interviews
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Krystal Biotech (KRYS) Is Up 5.6% After Stronger 2025 Profitability And EPS Growth Has The Bull Case Changed? - Sahm
Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 - Yahoo Finance
Krystal Biotech director Janney sells shares worth $10.1 million - Investing.com
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 700 Shares - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 37,895 Shares - MarketBeat
Daniel Janney Sells 7,741 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech director Janney sells shares worth $10.1 million By Investing.com - Investing.com Canada
Krystal Biotech Director Janney Daniel Sells Over $16 Million in Company Stock - TradingView
Vanguard Group Inc. Cuts Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Assessing Krystal Biotech (KRYS) Valuation After Earnings Beat And Profitability Milestone - simplywall.st
(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Krystal Biotech (NASDAQ:KRYS) Given New $284.00 Price Target at Guggenheim - MarketBeat
Guggenheim Raises Price Target for Krystal Biotech (KRYS) to $28 - GuruFocus
Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates - MSN
Risk On: Can Krystal Biotech Inc weather a recessionJuly 2025 Market Mood & Growth Focused Entry Reports - baoquankhu1.vn
Insider Unloading: Dino A Rossi Sells Options, Realizes $5.04M - Benzinga
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference - Bitget
Krystal Biotech execs to host TD Cowen fireside chat March 3 - Stock Titan
Krystal Biotech’s KB707 RMAT Win Opens New Lung Cancer Chapter - Yahoo Finance
Krystal Biotech Insider Sold Shares Worth $4,953,694, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech RMAT Win Shifts Focus To Broader Gene Therapy Pipeline - simplywall.st
Krystal Biotech (NASDAQ:KRYS) Director Sells $4,953,719.50 in Stock - MarketBeat
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million - Investing.com
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million By Investing.com - Investing.com India
Krystal Biotech Director Dino A. Rossi Sells Shares - TradingView
Director at Krystal Biotech (NASDAQ: KRYS) sells 18,950 shares - Stock Titan
Krystal Biotech, Inc. (KRYS) Stock Analysis: An Investor's Guide To A Promising 17% Upside - DirectorsTalk Interviews
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 - Yahoo Finance
Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating - Finviz
Aug EndMonth: What is the long term forecast for Giftify Inc stockInsider Selling & Expert Curated Trade Ideas - baoquankhu1.vn
Analysts Offer Predictions for Krystal Biotech Q2 Earnings - MarketBeat
Krystal Biotech, Inc. $KRYS Shares Sold by Aberdeen Group plc - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Trading Down 6.9%Here's Why - MarketBeat
Krystal Biotech Inc (KRYS) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):